Pharmacotherapy of dyslipidemias in the adult population

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 18, 2010, Pages 3041-3052

  Vigna, Giovanni Battista ^a   Fellin, Renato ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Cardiovascular risk; Dyslipidemia; HMG CoA reductase inhibitors; Hypercholesterolemia; Hypolipidemic drugs; Lipoproteins; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; CHOLESTEROL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NUTRACEUTICAL; PHYTOSTEROL; PITAVASTATIN; PRAVASTATIN; PROBUCOL; ROSUVASTATIN; SIMVASTATIN; THYROID HORMONE DERIVATIVE; TRIACYLGLYCEROL; UNINDEXED DRUG;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLELITHIASIS; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; FAMILIAL HYPERCHOLESTEROLEMIA; FLATULENCE; FLUSHING; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN SENSITIVITY; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIVER TOXICITY; MUSCLE DISEASE; MYALGIA; MYOGLOBINURIA; MYOPATHY; NEPHROTOXICITY; NEUROPATHY; PATIENT COMPLIANCE; PRURITUS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STROKE; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; WEAKNESS;

ADULT; ANIMALS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DRUG MONITORING; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; MEDICATION ADHERENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78649237834     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.513116     Document Type: Review

References (112)

1. Lipids. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. 8th edition. Mc Graw Hill, New York; 2001. p. 2705-988
2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
3. Ignatowski A. Uber die winkung des tierischen eiweisses auf die aorta und die parenchymatose organe der kanichen. Virchows Arch [A] 1909;198:248-70
4. Kritchevsky D. Laboratory models for atherosclerosis. Adv Drug Res 1974;9:41-53
5. Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol 2006;15:318-30
6. Muller C. Angina pectoris in hereditary xanthomatosis. Arch Int Med 1939;64:675-700
7. Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009;10:109-21
8. Dawber TR. The Framingham Study; the epidemiology of atherosclerotic disease. Harvard University Press, Cambridge; 1980
9. Toshima H, Koga Y, Keys A. Lessons for science for the Seven Countries Study. A 35-year collaborative experience in cardiovascular disease epidemiology. Springer, Tokyo; 1994
10. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:343-4
11. Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
12. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
13. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39
14. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-414
15. Brunzell JD, Davidson M, Furberg CD, et al. Consensus Conference Report. Lipoprotein management in patients with cardiometabolic risk. J Am Coll Cardiol 2008;51:1512-24
16. O'Keefe Jr JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-6
17. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy. A PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol 2005;46:1411-16
18. Denke MA. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 2005;112:3368-70
19. Kathiresan S. Lp (a) lipoprotein redux - from curious molecule to causal risk factor. N Engl J Med 2009;361:2573-4
20. Kiechl S, Willeit J. The mysteries of lipoprotein (a) and cardiovascular disease revisited. J Am Coll Cardiol 2010;55:2168-70
21. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
22. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med 2006;260:305-19
23. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy. A meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-13
24. De Caterina R, Scarano M, Marfisi RM, et al. Cholesterol-lowering interventions and stroke. Insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2010;55:198-211
25. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376
26. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia. Circulation 2010;121:1069-77
27. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 2007;62:879-87
28. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
29. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-51
30. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407
31. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45
32. Jarvik GP, Brunzell JD, Motulsky AG. Frequent detection of familial hypercholesterolemia mutations in familial combined hyperlipidemia. J Am Coll Cardiol 2008;52:1554-6
33. Wierzbicki AS, Graham CA, Young IS, Nicholls DP. Familial combined hyperlipidemia: under-defined and under-diagnosed? Curr Vasc Pharmacol 2008;6:13-22
34. Zuliani G, Vigna GB, Corsini A, et al. Severe hypercholesterolaemia: unusual inheritance in an Italian pedigree. Eur J Clin Invest 1995;25:322-31
35. Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab 2007;92:1581-9
36. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81
37. Civeira F; International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173:55-68
38. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105-12
39. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423
40. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. J Cardiovasc Risk 2002;9:33-9
41. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - The PRIMO Study. Cardiovasc Drugs Ther 2005;19:403-14
42. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association statin safety assessment Task Force. Am J Cardiol 2006;97(Suppl):89C-94C
43. Kuncl RW. Agents and mechanisms of toxic myopathy. Curr Opin Neurol 2009;22:506-15
44. Brown WV. Safety of statins. Curr Opin Lipidol 2008;19:558-62
45. Kinnman N, Hultcrantz R. Lipid lowering medications and hepatotoxicity. J Intern Med 2001;250:183-5
46. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-16
47. Kanbay M, Turgut F, Covic A, Goldsmith D. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence. J Nephrol 2009;22:598-609
48. Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf 2009;4:209-28
49. Kandiah N, Feldman HH. Therapeutic potential of statins in Alzheimer's disease. J Neurol Sci 2009;283:230-4
50. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453-63
51. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
52. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
53. Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107
54. Fruchart JC, Brewer Jr HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease: Fibrate Consensus Group. Am J Cardiol 1998;81:912-17
55. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008;5:542-53
56. Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus - a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol 2010;141:157-66
57. Jun. M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84
58. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005;366:1849-61
59. Fievet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr Opin Lipidol 2009;20:505-11
60. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
61. Wierzbicki AS. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr Opin Cardiol 2009;24:372-9
62. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99:3C-18C
63. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol 2008;153(Suppl):S68-75
64. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Ann Rev Pharmacol Toxicol 2008;48:79-106
65. Bays HE, Ballantyne C. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 2009;20:467-76
66. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008;101(Suppl):58B-62B
67. Treatment of High density lipoprotein to Reduce the Incidence of Vascular Events (HPS2-THRIVE). Available from: http://www.controlled-trials.com/ ISRCTN29503772. [Accessed 30 June 2010]
68. Niacin Plus Statin to Prevent Vascular Events (AIM-HIGH). Available from: http://clinicaltrials.gov/show/NCT00120289. [Accessed 30 June 2010]
69. Wierzbicki AS, Doherty E, Lumb PJ, et al. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005;21:333-8
70. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43
71. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
72. Howard WJ. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS. Nutr Metab Cardiovasc Dis 2010;20:295-300
73. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008;52:2198-205
74. Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid Intima-media Thickness and Overall Arterial Rigidity (VYCTOR) study. J Clin Pharmacol 2009;49:838-47
75. Drazen JM, D'Agostino RB, Ware JH, et al. Ezetimibe and cancer - an uncertain association. N Engl J Med 2008;359:1398-9
76. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009;10:2973-85
77. Bays HE, Goldberg RB. The 'forgotten' bile acid sequestrants: is now a good time to remember? Am J Ther 2007;14:567-80
78. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother 2007;8:2569-78
79. Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis 2009;207:16-23
80. Olsson AG. Is high HDL cholesterol always good? Ann Med 2009;41:11-8
81. Yamashita S, Hbujo H, Arai H, et al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2008;15:292-303
82. Katan MB, Grundy SM, Jones P. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003;78:965-78
83. Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr 2006;25:41-8
84. John S, Sorokin AV, Thompson PD. Phytosterols and vascular disease. Curr Opin Lipidol 2007;18:35-40
85. Sirtori CR, Galli C, Anderson JW, et al. Functional foods for dyslipidaemia and cardiovascular risk prevention. Nutr Res Rev 2009;22:244-61
86. Thompson GR; Heart-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198:247-55
87. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010;208:317-21
88. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85
89. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004;89:2601-7
90. Lemieux I, Poirier P, Bergeron J, et al. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? Can J Cardiol 2007;23(Suppl):23B-31B
91. Brunzell JD. Hypertriglyceridemia. N Engl J Med 2007;357:1009-17
92. Yang T, Pang CP, Tsang MW, et al. Pathogenic mutations of the lipoprotein lipase gene in Chinese patients with hypertriglyceridemic type 2 diabetes. Hum Mutat 2003;21:453
93. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54:585-94
94. Mattar M, Obeid O. Fish oil and the management of hypertriglyceridemia. Nutr Health 2009;20:41-9
95. Zuliani G, Galvani M, Leitersdorf E, et al. The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias. Curr Pharm des 2009;15:4087-93
96. Stefanutti C, Di Giacomo S, Vivenzio A, et al. Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study. Artif Organs 2009;33:1096-102
97. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52
98. Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol 2009;32:482-6
99. Neely RD. Who needs a lipid clinic? Int J Clin Pract 2008;62:847-9
100. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-7
101. Bellosta S, Paoletti R, Corsini A. Safety of statins. Focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(Suppl III):50-7
102. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106-7
103. Mahley Robert W, Bersot Thomas P. Chapter 35: Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th edition. McGrawHill, New York; 2006
104. Pasternak CR, Smith Jr SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024-8
105. Avis HJ, Hutten BA, Twickler MT, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? Curr Opin Lipidol 2009;20:484-90
106. Fruchart JC, Sacks F, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102(Suppl):1K-34K
107. Davidson MH. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep 2009;11:67-70
108. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010;362:906-16
109. Lowyck I, Fevery J. Statins in hepatobiliary diseases: effects, indications and risks. Acta Gastroenterol Belg 2007;70:381-8
110. Buchwald H, Varco RL, Boen JR, et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998;158:1253-61
111. Rodes-Cabau J, Tardif JC, Cossette M, et al. Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome. Am J Cardiol 2009;104:750-7
112. Arnaboldi L, Corsini A. Do structural differences in statins correlate with clinical efficacy? Curr Opin Lipidol 2010;21:298-304